A sentiment analysis of 7,823 mentor–patient conversations — cross-referenced with 12,400+ public forum posts, 14 peer-reviewed studies, and 3 national surveys. What patients share when they feel safe enough to be honest.
Your patients have fears, questions, and deal-breakers that determine whether they start treatment, stay on therapy, or quietly disappear. But they're not sharing them in clinical encounters, satisfaction surveys, or PSP intake calls. They're sharing them with people who've been there.
This report analyzes 7,823 mentor–patient conversations on the PatientPartner platform across six therapy areas, combined with a systematic review of 12,400+ public forum posts from Reddit, Inspire, HealthUnlocked, and PatientsLikeMe, plus 14 peer-reviewed qualitative studies and 3 national sentiment surveys.
What we found challenges fundamental assumptions about why patients drop off, what they actually need to hear, and when they make their real decision.
Non-adherence costs the U.S. healthcare system $100–300 billion annually and contributes to 125,000 preventable deaths per year. Most patient support programs answer the questions patients are comfortable asking in clinical settings — not the ones that actually drive adherence.
Clinical encounters capture what patients are willing to say in a 15-minute window with a medical authority. Peer conversations capture what they actually think.
Across 7,823 mentor conversations, we identified a consistent pattern: patients bring a different version of themselves to mentor conversations than they bring to clinical encounters.
"What are the side effects?"
"Be honest — how bad was the first month? Could you still work? Did your family notice?"
Patients want the lived experience of side effects, not the clinical profile. 78% of side-effect questions referenced daily-life impact.
"How long is recovery?"
"When did you actually feel like yourself again? Not what the doctor said — when did you really feel normal?"
Patients distrust clinical recovery timelines. 62% of conversations included "what's the real timeline?"
"Okay, I'll think about it."
"I've been putting this off for 4 months. I'm scared and I don't know if I'm making the right decision."
40.2% of patients report reluctance to start medication, but 88.6% of physicians estimate ≤20% of their patients are reluctant. Movement Disorder Society, n=469
"I understand the treatment plan."
"I nodded but I don't really understand why I need this specific drug. Is there something less aggressive?"
Comprehension signaling ≠ comprehension. 71% of patients in non-initiation studies cited inadequate understanding. Gil-Girbau et al., 2020
"No other questions."
"Can I ask you something personal? Did it affect my sex life / weight / ability to have kids?"
The most common "unasked" questions relate to intimate life impact — topics patients consider too personal for clinical settings.
Every fear-related statement across 7,823 conversations, categorized and ranked — then validated against forum data and peer-reviewed research.
While the fear hierarchy holds across the dataset, the intensity and expression varies significantly — suggesting one-size-fits-all patient education is structurally misaligned.
Patients delay biologics an avg. of 4.2 months after Rx. "I'd rather have the pain than feel like that" is recurring.
"When did you really feel normal?" asked in 71% of pre-surgical conversations.
Highest rate of "I haven't told anyone about this." 43% started with "I feel alone in this."
Highest resistance to initiation. Mentors who share their own resistance story have 2.1× higher engagement.
Emotional weight is categorically different. 91% include explicit expressions of fear.
Most questions per conversation: 4.7 avg. Decision complexity drives extended deliberation.
The single most powerful moment in a mentor conversation is when the mentor says a version of: "I felt the same way." This phrase appeared in 89% of conversations that resulted in treatment initiation — the "mutual understanding and solidarity" peers uniquely provide.
It's very difficult to open up to loved ones. But with someone who's been through it, you can just… be honest. They already know.
Most PSPs assume a linear journey: diagnosis → education → decision → action. Our data shows the real journey is nonlinear, emotionally gated, and has a specific inflection point.
We applied natural language processing (VADER + domain-specific healthcare NLP) to pre- and post-conversation patient language. The shift is both statistically significant and commercially meaningful.
Before: language characterized by uncertainty and isolation — "I don't know," "I'm scared," "nobody understands," "what if."
After: language shifts to agency and possibility — "I'm going to," "I didn't realize," "that makes me feel better," "I think I can do this."
This mirrors findings from a 2026 scoping review of NLP in cancer care, which identified "unmet emotional needs" as the dominant theme in patient-generated content. Wreyford et al., 2026
A 2025 JMIR study analyzing 7,543 dialysis community posts found the same pattern: 49.2% positive sentiment where peer support was present, compared to 26.2% negative without. JMIR, 2025
A separate analysis of 492,495 chronic disease community posts found that emotional support was the #1 activity (20.6% of posts), surpassing information-seeking.
We analyzed 24,700+ questions asked in mentor conversations and identified which most strongly correlate with treatment initiation within 30 days.
When a patient asks "Is it worth it?", conversion is 86%. None of the top 10 predictive questions are about mechanism of action or trial data — all are experiential. The content that moves patients isn't content. It's conversation.
Our findings don't exist in isolation. Here's how they map to published research, national surveys, and publicly available patient forum data.
67% of people say lived health experience qualifies someone as a health expert — up 11 points in 3 years. 45% of 18–34s believe a well-researched patient is equivalent to a physician.
Analysis of 31 patient narratives identified six core values; peer support ranked #1. Peers provide "mutual understanding and solidarity" HCPs cannot replicate.
A 2026 NLP scoping review found 4 themes predicting non-adherence: unmet emotional needs, poor communication, unclear concordance, and misinformation.
83% adherence success for face-to-face interventions vs. 38% phone-based and 33% paper-based. Peer interventions show 69–75% greater persistence.
We analyzed 12,400+ posts across Reddit (r/PsoriaticArthritis, r/ankylosingspondylitis, r/CrohnsDisease), Inspire.com, HealthUnlocked, and PatientsLikeMe to validate findings against organic patient expression.
The data above isn't theoretical. It's the pattern our clients are already seeing — and acting on — in their own programs.
Patient Partner is a unicorn in the industry. They are undoubtedly dedicated to the mission of positively impacting patients lives.
Patient Partner has been influential in helping patients understand the benefits of our product.
We knew patient trust was shifting, but seeing just how dramatically patients now prefer peer-to-peer engagement over traditional methods is a game-changer for our upcoming strategies.
Five structural changes that would measurably improve outcomes for pharma, med-tech, and clinical-trial organizations.
Use the inputs below to map this report's benchmarks onto your therapy area and program scale. No email required — the numbers are yours to keep.
Based on benchmarks from the 7,823-conversation dataset in this report. Individual results vary by brand, therapy area, and program design. We're happy to walk you through the math.
Turn this into a real plan →
Every patient support leader I talk to knows something is off. Their programs look complete on paper — education, nurses, copay cards, outreach — but patients still disappear. Initiation rates plateau. Adherence curves go flat around month three. Nobody can quite point to why.
After analyzing 7,823 mentor conversations, the pattern became impossible to miss: patients aren't dropping off because they don't have information. They're dropping off because the information they need isn't what anyone in a white coat can provide. They need to hear it from someone who's been there.
This report is the honest version of what we found. No product pitch, no hand-waving. If any of it resonates with what you're seeing in your own programs, I'd genuinely like to hear about it.
— George
Book 20 min with George →If you're still weighing whether this is the right fit, start here. These are the real questions pharma and med-device leaders ask us on the first call.
We don't replace your PSP — we sit alongside it. Your nurses, copay support, and education content handle the clinical conversations they're built for. PatientPartner handles the peer conversations your team simply can't (and shouldn't) have. Most clients integrate our mentor library as an add-on channel within their existing program flow, not a rebuild.
Typical implementation takes 4–6 weeks from kickoff to first mentor conversations. That covers mentor recruiting, therapy-area training, compliance review, and integration with your existing intake flow. We do the heavy lifting — your team reviews and approves. Most of your internal bandwidth goes into the first two weeks; after that we run it.
Yes. PatientPartner is HIPAA-compliant, SOC 2 certified, and built for regulated pharma/med-device environments. Every mentor is trained, vetted, and operates under documented guardrails. All conversations are logged, reviewable, and auditable. We've been through legal, medical, and regulatory review with some of the most conservative pharma brands — we'll walk your compliance team through every detail on the intro call.
Programs are priced as an annual subscription based on therapy area, patient volume, and mentor engagement hours. Use the ROI calculator above to pressure-test against your own numbers. In practice, most of our clients see payback inside the first 6 months driven by accelerated initiation alone — before counting the downstream adherence lift.
Minimal. We provide the mentor network, the conversation infrastructure, and the reporting. Your team reviews quarterly dashboards, helps refine the mentor match criteria as the program matures, and joins strategic check-ins. Most clients spend <2 hours / week on active program management after launch.
Our largest datasets are in autoimmune / biologics, surgical procedures, women's health, type 2 diabetes, oncology support, and medical devices — the six areas in this report. We've also run programs in rare disease, mental health, and gene therapy on a smaller scale. On the intro call we'll share which therapy-area benchmarks we can stand behind for your specific brand.
PatientPartner's mentor-driven platform gives you the peer conversations, sentiment data, and treatment-decision insights that traditional PSPs miss — structured, HIPAA-compliant, and connected to your outcomes data.
Transparency matters. Here's exactly how we collected, analyzed, and validated the data in this report.